Evidence map›Paper›PMID 42812201›Full record

ArticleFrontiers in pharmacology2026

Repurposing approved drugs as Pendrin (

Jianxing Lai, Duoduo Zhao, Xuwen Wang, Binben Wang, Jinliang Nan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jianxing Lai *Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Duoduo Zhao *Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xuwen WangCollege of Information Science and Electronic Engineering, Zhejiang University, Hangzhou, China.
Binben WangSchool of Mathematical Sciences, Zhejiang University, Hangzhou, China.
Jinliang NanDepartment of Cardiology of the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type-2 airway inflammation remodels the airway epithelium and drives mucus-associated transcriptional programs, making the epithelium an attractive source of drug targets in allergic asthma. Reanalyzing GSE193816, a lower-airway single-cell RNA-seq dataset of allergic asthma (AA) and allergic non-asthma control (AC) participants sampled before and after allergen challenge, a systematic epithelial prioritization ranked

Indexed as

asthmadrug repurposingmolecular dockingPendrin (SLC26A4)single-cell RNA-seq

Identifiers

PMID42812201
PMCPMC13619473

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.